Literature DB >> 10036612

The effects of dopaminergic D2 stimulation and blockade on smoking behavior.

N H Caskey1, M E Jarvik, W C Wirshing.   

Abstract

Researchers have hypothesized that dopamine mediates the reinforcing effects of stimulant drugs, including nicotine. Three experiments tested whether manipulating dopamine would alter human smoking behavior. Experiments used double-blind, repeated measures designs. In Experiment 1, 4 participants were given haloperidol (a dopamine antagonist; placebo, 0.5, and 1.0 mg) on 3 occasions. The smoking rate was faster in the 1.0 mg versus the placebo condition. In Experiment 2, 12 participants were given haloperidol (2.0 mg) and placebo on 2 occasions. The intercigarette interval was shorter at the expected time of peak drug concentration. In Experiment 3, 5 participants were given bromocriptine (a dopamine agonist, 2.5 mg) and placebo on 2 occasions. The smoking rate was significantly slower with bromocriptine. These results suggest that blockade of D2 receptors increases smoking whereas their stimulation decreases smoking.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10036612     DOI: 10.1037//1064-1297.7.1.72

Source DB:  PubMed          Journal:  Exp Clin Psychopharmacol        ISSN: 1064-1297            Impact factor:   3.157


  15 in total

1.  The selective dopamine D3 receptor antagonist SB-277011A reduces nicotine-enhanced brain reward and nicotine-paired environmental cue functions.

Authors:  Arlene C Pak; Charles R Ashby; Christian A Heidbreder; Maria Pilla; Jeremy Gilbert; Zheng-Xiong Xi; Eliot L Gardner
Journal:  Int J Neuropsychopharmacol       Date:  2006-08-31       Impact factor: 5.176

2.  Aripiprazole therapy for nicotine dependence.

Authors:  Sriram Ramaswamy; Subhash C Bhatia
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2006

Review 3.  The role of antipsychotics in smoking and smoking cessation.

Authors:  Annette M Matthews; Vanessa B Wilson; Suzanne H Mitchell
Journal:  CNS Drugs       Date:  2011-04       Impact factor: 5.749

4.  Resting-state EEG, impulsiveness, and personality in daily and nondaily smokers.

Authors:  Olga Rass; Woo-Young Ahn; Brian F O'Donnell
Journal:  Clin Neurophysiol       Date:  2015-05-14       Impact factor: 3.708

5.  Antipsychotic Treatment and Tobacco Craving in People With Schizophrenia.

Authors:  Heidi J Wehring; Stephen J Heishman; Robert P McMahon; Fang Liu; Stephanie Feldman; Heather Raley; Elaine Weiner; Deanna L Kelly
Journal:  J Dual Diagn       Date:  2017 Jan-Mar

6.  Varenicline as a smoking cessation aid in schizophrenia: effects on smoking behavior and reward sensitivity.

Authors:  Sunny J Dutra; Luke E Stoeckel; Sara V Carlini; Diego A Pizzagalli; A Eden Evins
Journal:  Psychopharmacology (Berl)       Date:  2011-06-22       Impact factor: 4.530

7.  Dopamine, urges to smoke, and the relative salience of drug versus non-drug reward.

Authors:  Tom P Freeman; Ravi K Das; Sunjeev K Kamboj; H Valerie Curran
Journal:  Soc Cogn Affect Neurosci       Date:  2014-02-12       Impact factor: 3.436

8.  Aripiprazole effects on self-administration and pharmacodynamics of intravenous cocaine and cigarette smoking in humans.

Authors:  Michelle R Lofwall; Paul A Nuzzo; Charles Campbell; Sharon L Walsh
Journal:  Exp Clin Psychopharmacol       Date:  2014-01-27       Impact factor: 3.157

9.  Secondhand smoke exposure and depressive symptoms.

Authors:  Frank C Bandiera; Kristopher L Arheart; Alberto J Caban-Martinez; Lora E Fleming; Kathryn McCollister; Noella A Dietz; William G Leblanc; Evelyn P Davila; John E Lewis; Berrin Serdar; David J Lee
Journal:  Psychosom Med       Date:  2009-11-30       Impact factor: 4.312

10.  Effects of acute tyrosine/phenylalanine depletion on the selective processing of smoking-related cues and the relative value of cigarettes in smokers.

Authors:  Brian Hitsman; James MacKillop; Anne Lingford-Hughes; Tim M Williams; Faheem Ahmad; Sally Adams; David J Nutt; Marcus R Munafò
Journal:  Psychopharmacology (Berl)       Date:  2007-11-25       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.